Novo Nordisk risk profile
34 Normal where most of the sector sits
Measured 21 October 2026 from NVO's filed statements. Recomputed nightly.
34 (Normal), driven by Market expectation at 57, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 57 | Elevated | Volatile | One-year price volatility — 46.0% |
| Operating pressure | 52 | Elevated | Worsening | Costs outgrowing revenue — +5.5 percentage points |
| Cash conversion | 45 | Elevated | Worsening | Capital spending against operating cash — 0.76x |
| Leverage and coverage | 21 | Normal | Stable | Current ratio — 0.80x |
| Competitive position | 21 | Normal | Stable | R&D-intensity gap against peers — -0.6 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.